Magnetic resonance imaging and histological evidence for the blockade of cuprizone-induced demyelination in C57BL/6 mice

Neuroscience

Volumn 202, Issue , 2012, Pages 446-453

  Chandran, P ^a   Upadhyay, J ^a   Markosyan, S ^a   Lisowski, A ^a   Buck, W ^a   Chin, C L ^a   Fox, G ^a   Luo, F ^a   Day, M ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Cuprizone; Demyelination; Mouse; MRI; Quetiapine; Schizophrenia

Indexed keywords

CUPRIZONE; MYELIN BASIC PROTEIN; QUETIAPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL MOUSE; CONTROLLED STUDY; DEMYELINATING DISEASE; DIFFUSION TENSOR IMAGING; DRUG EFFICACY; FEMALE; FRACTIONAL ANISOTROPY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL DENSITY; PHENOTYPE; PRIORITY JOURNAL; SCHIZOPHRENIA; T2 WEIGHTED NUCLEAR MAGNETIC RESONANCE IMAGING; TISSUE PRESERVATION; WEIGHT REDUCTION; WHITE MATTER; WHITE MATTER INTEGRITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; CHELATING AGENTS; CUPRIZONE; DATA INTERPRETATION, STATISTICAL; DEMYELINATING DISEASES; DIBENZOTHIAZEPINES; DIFFUSION TENSOR IMAGING; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C57BL; PHENOTYPE;

EID: 84856235235     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.10.051     Document Type: Article

References (43)

1. DeQuardo J.R., Keshavan M.S., Bookstein F.L., Bagwell W.W., Green W.D., Sweeney J.A., Haas G.L., Tandon R., Schooler N.R., Pettegrew J.W. Landmark-based morphometric analysis of first-episode schizophrenia. Biol Psychiatry 1999, 45:1321-1328.
2. Douaud G., Smith S., Jenkinson M., Behrens T., Johansen-Berg H., Vickers J., James S., Voets N., Watkins K., Matthews P.M., James A. Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia. Brain 2007, 130:2375-2386.
3. Downhill J.E., Buchsbaum M.S., Wei T., Spiegel-Cohen J., Hazlett E.A., Haznedar M.M., Silverman J., Siever L.J. Shape and size of the corpus callosum in schizophrenia and schizotypal personality disorder. Schizophr Res 2000, 42:193-208.
4. Franco-Pons N., Torrente M., Colomina M.T., Vilella E. Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. Toxicol Lett 2007, 169:205-213.
5. Hafner H., Riecher-Rossler A., An Der Heiden W., Maurer K., Fatkenheuer B., Loffler W. Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia. Psychol Med 1993, 23:925-940.
6. Hahn N., Eisen R.J., Eisen L., Lane R.S. Ketamine-medetomidine anesthesia with atipamezole reversal: practical anesthesia for rodents under field conditions. Lab Anim (NY) 2005, 34:48-51.
7. Hakak Y., Walker J.R., Li C., Wong W.H., Davis K.L., Buxbaum J.D., Haroutunian V., Fienberg A.A. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A 2001, 98:4746-4751.
8. Hibbits N., Pannu R., John Wu T., Armstrong R.C. Cuprizone demyelination of the corpus callosum in mice correlates with altered social interaction and impaired bilateral sensorimotor coordination. ASN Neuro 2009, 1(3). pii: e00013.
9. Inglese M., Bester M. Diffusion imaging in multiple sclerosis: research and clinical implications. NMR Biomed 2010, 23(7):865-872.
10. Jaaro-Peled H. Gene models of schizophrenia: DISC1 mouse models. Prog Brain Res 2009, 179:75-86.
11. Jaaro-Peled H., Ayhan Y., Pletnikov M.V., Sawa A. Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models. Schizophr Bull 2010, 36:301-313.
12. Jenkinson M., Bannister P., Brady M., Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 2002, 17:825-841.
13. Kanaan R., Barker G., Brammer M., Giampietro V., Shergill S., Woolley J., Picchioni M., Toulopoulou T., McGuire P. White matter microstructure in schizophrenia: effects of disorder, duration and medication. Br J Psychiatry 2009, 194:236-242.
14. Kipp M., Clarner T., Dang J., Copray S., Beyer C. The cuprizone animal model: new insights into an old story. Acta Neuropathol 2009, 118:723-736.
15. Kohler J., Heilmeyer H., Volk B. Multiple sclerosis presenting as chronic atypical psychosis. J Neurol Neurosurg Psychiatry 1988, 51:281-284.
16. Koutsoudaki P.N., Skripuletz T., Gudi V., Moharregh-Khiabani D., Hildebrandt H., Trebst C., Stangel M. Demyelination of the hippocampus is prominent in the cuprizone model. Neurosci Lett 2009, 451:83-88.
17. Kubicki M., McCarley R., Westin C.F., Park H.J., Maier S., Kikinis R., Jolesz F.A., Shenton M.E. A review of diffusion tensor imaging studies in schizophrenia. J Psychiatr Res 2007, 41:15-30.
18. Kumar S., Biancotti J.C., Yamaguchi M., de Vellis J. Combination of growth factors enhances remyelination in a cuprizone-induced demyelination mouse model. Neurochem Res 2007, 32:783-797.
19. Luo F., Seifert T.R., Edalji R., Loebbert R.W., Hradil V.P., Harlan J., Schmidt M., Nimmrich V., Cox B.F., Fox G.B. Non-invasive characterization of beta-amyloid (1-40) vasoactivity by functional magnetic resonance imaging in mice. Neuroscience 2008, 155:263-269.
20. Makinodan M., Yamauchi T., Tatsumi K., Okuda H., Takeda T., Kiuchi K., Sadamatsu M., Wanaka A., Kishimoto T. Demyelination in the juvenile period, but not in adulthood, leads to long-lasting cognitive impairment and deficient social interaction in mice. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:978-985.
21. Marcotte E.R., Pearson D.M., Srivastava L.K. Animal models of schizophrenia: a critical review. J Psychiatry Neurosci 2001, 26:395-410.
22. Meltzer H.Y. Action of atypical antipsychotics. Am J Psychiatry 2002, 159:153-154. author reply 154-155.
23. Meltzer H.Y., Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 2008, 172:177-197.
24. Pasquini L.A., Calatayud C.A., Bertone Uña A.L., Millet V., Pasquini J.M., Soto E.F. The neurotoxic effect of cuprizone on oligodendrocytes depends on the presence of pro-inflammatory cytokines secreted by microglia. Neurochem Res 2007, 32:279-292.
25. Richelson E., Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000, 68:29-39.
26. Rovaris M., Gass A., Bammer R., Hickman S.J., Ciccarelli O., Miller D.H., Filippi M. Dffusion MRI in multiple sclerosis. Neurology 2005, 65:1526-1532.
27. Sachdev P., Brodaty H., Rose N., Cathcart S. Schizophrenia with onset after age 50 years. 2: Neurological, neuropsychological and MRI investigation. Br J Psychiatry 1999, 175:416-421.
28. Shenton M.E., Dickey C.C., Frumin M., McCarley R.W. A review of MRI findings in schizophrenia. Schizophr Res 2001, 49:1-52.
29. Skripuletz T., Lindner M., Kotsiari A., Garde N., Fokuhl J., Linsmeier F., Trebst C., Stangel M. Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent. Am J Pathol 2008, 172:1053-1061.
30. Song S.K., Yoshino J., Le T.Q., Lin S.J., Sun S.W., Cross A.H., Armstrong R.C. Demyelination increases radial diffusivity in corpus callosum of mouse brain. Neuroimage 2005, 26:132-140.
31. Stevens J.R. Schizophrenia: reproductive hormones and the brain. Am J Psychiatry 2002, 159:713-719.
32. Sun S.W., Liang H.F., Trinkaus K., Cross A.H., Armstrong R.C., Song S.K. Noninvasive detection of cuprizone induced axonal damage and demyelination in the mouse corpus callosum. Magn Reson Med 2006, 55:302-308.
33. Tkachev D., Mimmack M.L., Ryan M.M., Wayland M., Freeman T., Jones P.B., Starkey M., Webster M.J., Yolken R.H., Bahn S. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003, 362:798-805.
34. Torkildsen O., Brunborg L.A., Myhr K.M., Bø L. The cuprizone model for demyelination. Acta Neurol Scand Suppl 2008, 188:72-76.
35. Whitford T.J., Grieve S.M., Farrow T.F., Gomes L., Brennan J., Harris A.W., Gordon E., Williams L.M. Volumetric white matter abnormalities in first-episode schizophrenia: a longitudinal, tensor-based morphometry study. Am J Psychiatry 2007, 164:1082-1089.
36. Wu Q.Z., Yang Q., Cate H.S., Kemper D., Binder M., Wang H.X., Fang K., Quick M.J., Marriott M., Kilpatrick T.J., Egan G.F. MRI identification of the rostral-caudal pattern of pathology within the corpus callosum in the cuprizone mouse model. J Magn Reson Imaging 2008, 27:446-453.
37. Xiao L., Xu H., Zhang Y., Wei Z., He J., Jiang W., Li X., Dyck L.E., Devon R.M., Deng Y., Li X.M. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol Psychiatry 2008, 13:697-708.
38. Xu H., Yang H.J., McConomy B., Browning R., Li X.M. Behavioral and neurobiological changes in C57BL/6 mouse exposed to cuprizone: effects of antipsychotics. Front Behav Neurosci 2010, 4:8.
39. Xu H., Yang H.J., Zhang Y., Clough R., Browning R., Li X.M. Behavioral and neurobiological changes in C57BL/6 mice exposed to cuprizone. Behav Neurosci 2009, 123:418-429.
40. Yang H.J., Wang H., Zhang Y., Xiao L., Clough R.W., Browning R., Li X.M., Xu H. Region-specific susceptibilities to cuprizone-induced lesions in the mouse forebrain: implications for the pathophysiology of schizophrenia. Brain Res 2009, 1270:121-130.
41. Yu O., Steibel J., Mauss Y., Guignard B., Eclancher B., Chambron J., Grucker D. Remyelination assessment by MRI texture analysis in a cuprizone mouse model. Magn Reson Imaging 2004, 22:1139-1144.
42. Zhang J., Jones M.V., McMahon M.T., Mori S., Calabresi P.A. In vivo and ex vivo diffusion tensor imaging of cuprizone-induced demyelination in the mouse corpus callosum. Magn Reson Med 2011, 10.1002/mrm.23032.
43. Zhang Y., Xu H., Jiang W., Xiao L., Yan B., He J., Wang Y., Bi X., Li X., Kong J., Li X.M. Quetiapine alleviates the cuprizone-induced white matter pathology in the brain of C57BL/6 mouse. Schizophr Res 2008, 106:182-191.